AB Science tiendra une conférence virtuelle sur sa plateforme de déstabilisateurs de microtubules le jeudi 16 mars 2023, de 18h à 19h
15 mars 2023 13h05 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR SA PLATEFORME DE DESTABILISATEURS DE MICROTUBULES LE JEUDI 16 MARS 2023, DE 18h A 19h Paris, 15 mars 2023, 18h AB Science SA...
AB Science annonce une première réponse complète de la moelle osseuse chez un patient atteint de leucémie myéloïde aigue réfractaire en rechute, à très faible dose, dans son essai clinique de phase I/II avec AB8939 (AB18001)
13 mars 2023 13h10 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE UNE PREMIÈRE RÉPONSE COMPLÈTE DE LA MOELLE OSSEUSE CHEZ UN PATIENT ATTEINT DE LEUCÉMIE MYÉLOÏDE AIGUË (LMA) RÉFRACTAIRE EN RECHUTE, A TRÈS FAIBLE DOSE, DANS...
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
13 mars 2023 13h10 HE
|
AB Science
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENT FROM THE VERY LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL...
Cytek® Biosciences Introduces New 20-Color AML Panel
07 mars 2023 17h00 HE
|
Cytek Biosciences, Inc.
FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid...
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
23 févr. 2023 16h03 HE
|
Kura Oncology, Inc.
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of...
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
09 févr. 2023 07h30 HE
|
Kura Oncology, Inc.
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe...
Acute Myeloid Leukemia Diagnostics Market Set to Reach Valuation of USD 5,866.25 Million by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis
23 janv. 2023 07h50 HE
|
Data Bridge Market Research
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Acute Myeloid Leukemia Diagnostics Market Study by in-depth analysis of the current scenario, the Market...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
10 déc. 2022 10h30 HE
|
Kura Oncology, Inc.
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated...
Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports
19 oct. 2022 06h13 HE
|
Growth Plus Reports
Pune, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute myeloid leukemia market is expected to clock US$ 4.31 billion by 2030 and to...
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape
06 sept. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape DelveInsight’s...